Want to see CADL full AI Analyst Report?
CADL Stock Chart & Stats
$13.28
$0.40(4.18%)
At close: 4:00 PM EDT
$13.28
$0.40(4.18%)
Day’s Range― - ―
52-Week Range$4.35 - $14.00
Previous Close$10.1
Volume1.27M
Average Volume (3M)1.14M
Market Cap
$614.44M
Enterprise Value$611.50M
Total Cash (Recent Filing)$201.56M
Total Debt (Recent Filing)$49.52M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 05, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding76,518,560
10 Day Avg. Volume1,034,880
30 Day Avg. Volume1,144,975
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)5.76
Price to Sales (P/S)0.00
P/FCF Ratio-7.69
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.36
Forecast
1Y Price Target
$21.50Price Target Upside61.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ValidationPositive randomized phase 3 results provide meaningful clinical validation for the lead immunotherapy and strengthen the potential path toward regulatory submission. Success across prostate, pancreatic, and lung cancer programs could support broader commercial opportunity if subsequent regulatory milestones are achieved.
Funding RunwayThe reported cash position and additional financing arrangements provide resources to continue clinical development and prepare for commercialization. This funding base can extend execution capacity through important regulatory milestones, although some facilities are contingent or debt-based rather than internally generated.
Regulatory ExpertiseAdding an independent director with extensive regulatory, quality, and drug-development experience strengthens governance during a pivotal transition toward a potential biologics application. Her background may improve oversight of submission planning and commercial-readiness work as the lead program advances.
Bears Say
No Recurring RevenueThe absence of recurring revenue means Candel remains dependent on financing and future clinical success rather than an established operating franchise. Deep losses also show that current development activity has not yet translated into commercial earnings or operating leverage.
Accelerating Cash BurnWorsening operating and free cash flow indicates that the cost of advancing the pipeline is increasing faster than internally generated funding, which is absent at this stage. Persistent cash consumption can shorten runway and increase the need for additional capital before revenue begins.
Rising Financing RiskThe sharp increase in debt raises financial risk for a company that is not yet producing revenue and remains deeply unprofitable. Greater leverage can reduce flexibility, add repayment obligations, and increase the likelihood that future development will require further debt or equity financing.
Candel Therapeutics News
CADL FAQ
What was Candel Therapeutics’s price range in the past 12 months?
Candel Therapeutics lowest stock price was $4.35 and its highest was $14.00 in the past 12 months.
What is Candel Therapeutics’s market cap?
Candel Therapeutics’s market cap is $614.44M.
When is Candel Therapeutics’s upcoming earnings report date?
Candel Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 11 days.
How were Candel Therapeutics’s earnings last quarter?
Candel Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.238 by -$0.282.
Is Candel Therapeutics overvalued?
According to Wall Street analysts Candel Therapeutics’s price is currently Undervalued.
Does Candel Therapeutics pay dividends?
Candel Therapeutics does not currently pay dividends.
What is Candel Therapeutics’s EPS estimate?
Candel Therapeutics’s EPS estimate is -0.34.
How many shares outstanding does Candel Therapeutics have?
Candel Therapeutics has 76,518,560 shares outstanding.
What happened to Candel Therapeutics’s price movement after its last earnings report?
Candel Therapeutics reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.238. Following the earnings report the stock price went up 10.487%.
Which hedge fund is a major shareholder of Candel Therapeutics?
Currently, no hedge funds are holding shares in CADL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Candel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.50 (61.90% Upside)
$21.50 (61.90% Upside)
Blogger Sentiment
Bullish
CADL Sentiment 96%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 98.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.22%
12-Months-Change
Fundamentals
Return on Equity
-89.38%
Trailing 12-Months
Asset Growth
96.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Candel Therapeutics
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
CADL Stock 12 Month Forecast
Average Price Target
$21.50
▲(61.90% Upside)
Technical Analysis
CytomX Therapeutics
―
Replimune Group
―
Immatics
―
Lyell Immunopharma
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
8.86% Insiders
16.61% Mutual Funds
0.39% Other Institutional Investors
60.68% Public Companies and
Individual Investors